{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:38:51Z","timestamp":1792690731969,"version":"4.5.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>EUCAST has established clinical breakpoints and epidemiological cutoff values (ECOFFs) for Candida spp. However, limited data are available for 5-flucytosine (5-FC). We assessed the in vitro susceptibility of 5-FC against a large collection of clinical Candida species using EUCAST methodology and determined the associated ECOFFs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A total of 5622 Candida isolates were collected from patients across the Netherlands between 2008 and 2024. 5-FC MICs were determined using the EUCAST microbroth dilution reference method. Furthermore, MICs were extracted from the EUCAST website. The MICs from this study and those extracted were used to determine ECOFFs and local ECOFFs (L-ECOFFs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>5-FC exhibited potent in vitro activity against C. albicans, N. glabratus and C. parapsilosis, while decreased susceptibility was observed for C. tropicalis, Pichia species, K. marxianus, Y. lipolytica, and C. auris. The ECOFFs (mg\/L) and the percentages of WT isolates for 5-FC were: C. albicans: 0.5 (97.2%), N. glabratus: 0.5 (96.6%), C. parapsilosis: 0.5 (99.5%) and P. kudriavzevii: 8 (99.4%). The L-ECOFF (mg\/L) and the percentages of WT isolates for 5-FC were: C. dubliniensis: 0.25 (96.8%), C. tropicalis: 0.25 (67.2%), K. marxianus: 0.25 (48.0%), C. lusitaniae: 0.25 (86.5%), M. guillermondii: 0.125 (95.9%) and P. norvegiensis: 8 (94.2%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>5-FC remains a valuable drug to manage difficult-to-treat invasive Candida infections. In vitro susceptibility cannot be predicted based on species identification for most Candida species, but requires MIC-testing. ECOFFs will help to interpret the MICs to support treatment decisions.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jacamr\/dlae153","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T10:28:06Z","timestamp":1728037686000},"source":"Crossref","is-referenced-by-count":11,"title":["Wild-type MIC distributions and epidemiological cutoff values for 5-flucytosine and <i>Candida<\/i> species as determined by EUCAST broth microdilution"],"prefix":"10.1093","volume":"6","author":[{"given":"Fatima Zohra","family":"Delma","sequence":"first","affiliation":[{"name":"Radboudumc-CWZ Center of Expertise for Mycology , Radboudumc Community for Infectious Diseases, Radboudumc, Nijmegen ,","place":["the Netherlands"]},{"name":"Department of Medical Microbiology, Radboudumc , Nijmegen ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem J G","family":"Melchers","sequence":"additional","affiliation":[{"name":"Radboudumc-CWZ Center of Expertise for Mycology , Radboudumc Community for Infectious Diseases, Radboudumc, Nijmegen ,","place":["the Netherlands"]},{"name":"Department of Medical Microbiology, Radboudumc , Nijmegen ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8600-9860","authenticated-orcid":false,"given":"Paul E","family":"Verweij","sequence":"additional","affiliation":[{"name":"Radboudumc-CWZ Center of Expertise for Mycology , Radboudumc Community for Infectious Diseases, Radboudumc, Nijmegen ,","place":["the Netherlands"]},{"name":"Department of Medical Microbiology, Radboudumc , Nijmegen ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4031-0778","authenticated-orcid":false,"given":"Jochem B","family":"Buil","sequence":"additional","affiliation":[{"name":"Radboudumc-CWZ Center of Expertise for Mycology , Radboudumc Community for Infectious Diseases, Radboudumc, Nijmegen ,","place":["the Netherlands"]},{"name":"Department of Medical Microbiology, Radboudumc , Nijmegen ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"key":"2024103013304263900_dlae153-B1","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.3389\/fmicb.2016.02173","article-title":"Azole antifungal resistance in Candida albicans and emerging non-albicans Candida species","volume":"7","author":"Whaley","year":"2017","journal-title":"Front Microbiol"},{"key":"2024103013304263900_dlae153-B2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1128\/CMR.00029-06","article-title":"Epidemiology of invasive candidiasis: a persistent public health problem","volume":"20","author":"Pfaller","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"2024103013304263900_dlae153-B3","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024103013304263900_dlae153-B4","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/cid\/civ1194","article-title":"Executive summary: clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024103013304263900_dlae153-B5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/jac\/46.2.171","article-title":"Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions","volume":"46","author":"Vermes","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"2024103013304263900_dlae153-B6","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3390\/jof7110909","article-title":"Molecular mechanisms of 5-fluorocytosine resistance in yeasts and filamentous fungi","volume":"7","author":"Delma","year":"2021","journal-title":"J Fungi"},{"key":"2024103013304263900_dlae153-B7","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3947\/ic.2022.0008","article-title":"Candida auris: an overview of the emerging drug-resistant fungal infection","volume":"54","author":"Sanyaolu","year":"2022","journal-title":"Infect Chemother"},{"key":"2024103013304263900_dlae153-B8","doi-asserted-by":"publisher","first-page":"957021","DOI":"10.3389\/ffunb.2022.957021","article-title":"The emerging threat antifungal-resistant Candida tropicalis in humans, animals, and environment","volume":"3","author":"Lima","year":"2022","journal-title":"Front Fungal Biol"},{"key":"2024103013304263900_dlae153-B9","doi-asserted-by":"publisher","first-page":"e470","DOI":"10.1016\/S2666-5247(23)00067-8","article-title":"Worldwide emergence of fluconazole-resistant Candida parapsilosis: current framework and future research roadmap","volume":"4","author":"Daneshnia","year":"2023","journal-title":"Lancet Microbe"},{"key":"2024103013304263900_dlae153-B10","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1128\/JCM.00248-12","article-title":"Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. As determined by CLSI broth microdilution","volume":"50","author":"Pfaller","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2024103013304263900_dlae153-B11","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1128\/JCM.01730-12","article-title":"Comparison of three statistical methods for establishing tentative wild-type population and epidemiological cutoff values for echinocandins, amphotericin B, flucytosine, and six Candida species as determined by the colorimetric sensititre YeastOne method","volume":"50","author":"Cant\u00f3n","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2024103013304263900_dlae153-B12","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/j.1469-0691.2008.02086.x","article-title":"Subcommittee on antifungal susceptibility testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing. EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds","volume":"14","author":"Rodriguez-Tudela","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"2024103013304263900_dlae153-B13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/jac\/dkg312","article-title":"European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria","volume":"52","author":"Kahlmeter","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2024103013304263900_dlae153-B14","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/j.1469-0691.2006.01377.x","article-title":"Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values","volume":"12","author":"Turnidge","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"2024103013304263900_dlae153-B15","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1128\/AAC.01256-09","article-title":"Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media","volume":"54","author":"Arendrup","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013304263900_dlae153-B16","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1128\/AAC.00156-08","article-title":"Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus","volume":"52","author":"Rodriguez-Tudela","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013304263900_dlae153-B17","doi-asserted-by":"publisher","first-page":"3680","DOI":"10.1128\/AAC.00369-06","article-title":"Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and impact of the MIC, growth rate, and resistance genotype on the antifungal effect","volume":"50","author":"Hope","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013304263900_dlae153-B18","doi-asserted-by":"publisher","first-page":"e0010022","DOI":"10.1128\/cmr.00100-22","article-title":"Wild-type distributions of minimum inhibitory concentrations and epidemiological cut-off values-laboratory and clinical utility","volume":"36","author":"Kahlmeter","year":"2023","journal-title":"Clin Microbiol Rev"},{"key":"2024103013304263900_dlae153-B19","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.diagmicrobio.2014.03.004","article-title":"Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp","volume":"79","author":"Pfaller","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2024103013304263900_dlae153-B20","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.cmi.2020.06.007","article-title":"How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST)","volume":"26","author":"Arendrup","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2024103013304263900_dlae153-B21","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.3390\/microorganisms10061208","article-title":"Continuing shifts in epidemiology and antifungal susceptibility highlight the need for improved disease management of invasive candidiasis","volume":"10","author":"Parslow","year":"2022","journal-title":"Microorganisms"},{"key":"2024103013304263900_dlae153-B22","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/PL00011265","article-title":"Flucytosine primary resistance in Candida species and Cryptococcus neoformans","volume":"20","author":"Cuenca-Estrella","year":"2001","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2024103013304263900_dlae153-B23","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1128\/AAC.46.11.3518-3521.2002","article-title":"In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods","volume":"46","author":"Pfaller","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013304263900_dlae153-B24","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1128\/JCM.00328-10","article-title":"Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: results from the global SENTRY antimicrobial surveillance program (2008)","volume":"48","author":"Messer","year":"2010","journal-title":"J Clin Microbiol"},{"key":"2024103013304263900_dlae153-B25","first-page":"63","article-title":"In-vitro activity of 5-fluorocytosine against 1,021 Spanish clinical isolates of Candida and other medically important yeasts","volume":"21","author":"Quind\u00f3s","year":"2004","journal-title":"Rev Iberoam Micol"},{"key":"2024103013304263900_dlae153-B26","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1128\/AAC.48.1.262-266.2004","article-title":"Flucytosine resistance is restricted to a single genetic clade of Candida albicans","volume":"48","author":"Pujol","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013304263900_dlae153-B27","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1128\/AAC.48.6.2223-2227.2004","article-title":"Clade-specific flucytosine resistance is due to a single nucleotide change in the FUR1 gene of Candida albicans","volume":"48","author":"Dodgson","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013304263900_dlae153-B28","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.1128\/JCM.43.8.4026-4036.2005","article-title":"Novel 5-flucytosine-resistant clade of Candida dubliniensis from Saudi Arabia and Egypt identified by Cd25 fingerprinting","volume":"43","author":"Al Mosaid","year":"2005","journal-title":"J Clin Microbiol"},{"key":"2024103013304263900_dlae153-B29","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1093\/jac\/45.3.408","article-title":"Primary resistance to flucytosine among clinical isolates of Candida spp","volume":"45","author":"Barchiesi","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"2024103013304263900_dlae153-B30","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/jac\/dkz568","article-title":"MIC distributions for amphotericin B, fluconazole, itraconazole, voriconazole, flucytosine and anidulafungin and 35 uncommon pathogenic yeast species from the UK determined using the CLSI broth microdilution method","volume":"75","author":"Borman","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2024103013304263900_dlae153-B31","doi-asserted-by":"publisher","first-page":"e02055-18","DOI":"10.1128\/jcm.02055-18","article-title":"Candida auris isolates of the Southern Asian and South African lineages exhibit different phenotypic and antifungal susceptibility profiles in vitro","volume":"57","author":"Szekely","year":"2019","journal-title":"J Clin Microbiol"},{"key":"2024103013304263900_dlae153-B32","doi-asserted-by":"publisher","first-page":"e0051721","DOI":"10.1128\/aac.00517-21","article-title":"In vitro antifungal resistance of Candida auris isolates from bloodstream infections, South Africa","volume":"65","author":"Maphanga","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013304263900_dlae153-B33","doi-asserted-by":"publisher","first-page":"5121","DOI":"10.2147\/IDR.S383785","article-title":"Candida lusitaniae: biology, pathogenicity, virulence factors, diagnosis, and treatment","volume":"15","author":"Mendoza-Reyes","year":"2022","journal-title":"Infect Drug Resist"},{"key":"2024103013304263900_dlae153-B34","doi-asserted-by":"publisher","first-page":"94","DOI":"10.5114\/pm.2018.77310","article-title":"Candida lusitaniae\u2013a case report of an intraperitoneal infection","volume":"17","author":"Wawrysiuk","year":"2018","journal-title":"Prz Menopauzalny"},{"key":"2024103013304263900_dlae153-B35","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1128\/AAC.46.2.578-581.2002","article-title":"Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined by microdilution, Etest, and time-kill methods","volume":"46","author":"Ernst","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2024103013304263900_dlae153-B36","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1093\/mmy\/myz124","article-title":"Antifungal susceptibility, genotyping, resistance mechanism, and clinical profile of Candida tropicalis blood isolates","volume":"58","author":"Arastehfar","year":"2020","journal-title":"Med Mycol"},{"key":"2024103013304263900_dlae153-B37","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3201\/eid1404.071083","article-title":"Clonal population of flucytosine-resistant Candida tropicalis from blood cultures, Paris, France","volume":"14","author":"Desnos-Ollivier","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"2024103013304263900_dlae153-B38","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/jac\/dkl555","article-title":"In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest","volume":"59","author":"Fleck","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2024103013304263900_dlae153-B39","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/myc.13095","article-title":"Yarrowia lipolytica causes sporadic cases and local outbreaks of infections and colonisation","volume":"63","author":"Desnos-Ollivier","year":"2020","journal-title":"Mycoses"},{"key":"2024103013304263900_dlae153-B40","doi-asserted-by":"publisher","first-page":"e03203-23","DOI":"10.1128\/spectrum.03203-23","article-title":"Antifungal susceptibility profile and local epidemiological cut-off values of Yarrowia (Candida) lipolytica: an emergent and rare opportunistic yeast","volume":"12","author":"Yu","year":"2024","journal-title":"Microbiol Spectr"},{"key":"2024103013304263900_dlae153-B41","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1128\/AAC.00605-10","article-title":"Mutational analysis of flucytosine resistance in Candida glabrata","volume":"54","author":"Edlind","year":"2010","journal-title":"Antimicrob Agents Chemother"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/6\/5\/dlae153\/60198283\/dlae153.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/6\/5\/dlae153\/60198283\/dlae153.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T18:59:40Z","timestamp":1730314780000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlae153\/7810653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlae153","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,9,3]]},"article-number":"dlae153"}}